{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:13:18Z","timestamp":1787008398949,"version":"build-2736575974"},"reference-count":66,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"vor","delay-in-days":727,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1093\/annonc\/mdx358","type":"journal-article","created":{"date-parts":[[2017,7,11]],"date-time":"2017-07-11T15:17:57Z","timestamp":1499786277000},"page":"2680-2690","source":"Crossref","is-referenced-by-count":18,"title":["Maintenance therapy following induction chemoimmunotherapy in patients with diffuse large B-cell lymphoma: current perspective"],"prefix":"10.1016","volume":"28","author":[{"given":"N.M.","family":"Reddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Thieblemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdx358_bb0010","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mdx358_bb0015","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx358_bb0020","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma","volume":"89","author":"The Non-Hodgkin's Lymphoma Classification Project","year":"1997","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx358_bb0025","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.critrevonc.2012.12.009","article-title":"Diffuse large B-cell lymphoma","volume":"87","author":"Martelli","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1093\/annonc\/mdx358_bb0030","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/2040620712464508","article-title":"Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma","volume":"4","author":"Dunleavy","year":"2013","journal-title":"Ther Adv Hematol"},{"key":"10.1093\/annonc\/mdx358_bb0035","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2016.67.2980","article-title":"Randomized trial comparing R-CHOP versus high-dose sequential chemotherapy in high-risk patients with diffuse large B-cell lymphomas","volume":"34","author":"Cortelazzo","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx358_bb0040","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdx358_bb0045","volume":"124","author":"Le Gouill","year":"2014","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1093\/annonc\/mdx358_bb0050","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00277-014-2271-1","article-title":"Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy","volume":"94","author":"Rovira","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1093\/annonc\/mdx358_bb0055","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx358_bb0060","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx358_bb0065","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/ajh.21406","article-title":"Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma","volume":"84","author":"Broyde","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1093\/annonc\/mdx358_bb0070","doi-asserted-by":"crossref","first-page":"7070","DOI":"10.1182\/blood-2011-04-345256","article-title":"Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium","volume":"117","author":"Salles","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx358_bb0075","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1002\/cncr.27396","article-title":"Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab","volume":"118","author":"Akyurek","year":"2012","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdx358_bb0080","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx358_bb0085","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3324\/haematol.2012.066209","article-title":"Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study","volume":"98","author":"Visco","year":"2013","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdx358_bb0090","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.18632\/oncotarget.6262","article-title":"Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma","volume":"7","author":"Ye","year":"2016","journal-title":"Oncotarget"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdx358_bb0095","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1038\/modpathol.2012.178","article-title":"Aggressive B-cell lymphomas: how many categories do we need?","volume":"26","author":"Said","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1093\/annonc\/mdx358_bb0100","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx358_bb0105","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdx358_bb0110","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx358_bb0115","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx358_bb0120","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.2015.61.9288","article-title":"Prognostic significance of diffuse large B-cell lymphoma cell of origin: seeing the forest and the trees","volume":"33","author":"Younes","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx358_bb0125","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1182\/blood-2005-01-0272","article-title":"[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome","volume":"106","author":"Haioun","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx358_bb0130","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1200\/JCO.2009.26.5942","article-title":"Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma","volume":"28","author":"Moskowitz","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx358_bb0135","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nm.3120","article-title":"Metastasis awakening: targeting dormant cancer","volume":"19","author":"Aguirre-Ghiso","year":"2013","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdx358_bb0140","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","article-title":"Event-free survival at 24months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"32","author":"Maurer","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx358_bb0145","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1073\/pnas.1205299110","article-title":"Genetic heterogeneity of diffuse large B-cell lymphoma","volume":"110","author":"Zhang","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdx358_bb0150","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx358_bb0155","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1002\/cncr.26135","article-title":"Higher response to lenalidomide in relapsed\/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype","volume":"117","author":"Hernandez-Ilizaliturri","year":"2011","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdx358_bb0160","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.2007.06841.x","article-title":"Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo","volume":"140","author":"Reddy","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdx358_bb0165","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/0008-5472.CAN-06-2317","article-title":"Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells","volume":"67","author":"Verhelle","year":"2007","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdx358_bb0170","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.2975.2975","article-title":"In vivo evaluation of immunomodulating effects of lenalidomide on tumor cell microenvironment as a possible underlying mechanism of the antitumor effects observed in patients with chronic lymphocytic leukemia","volume":"106","author":"Chanan-Khan","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx358_bb0175","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1182\/blood-2005-10-4184","article-title":"Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications","volume":"108","author":"Chang","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx358_bb0180","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2174\/1568008033340207","article-title":"Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agents","volume":"3","author":"Marriott","year":"2003","journal-title":"Curr Drug Targets Immune Endocr Metabol Disord"},{"key":"10.1093\/annonc\/mdx358_bb0185","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx358_bb0190","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdx358_bb0195","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"10.1093\/annonc\/mdx358_bb0200","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kronke","year":"2014","journal-title":"Science"},{"key":"10.1093\/annonc\/mdx358_bb0205","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.)","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdx358_bb0210","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","article-title":"Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma","volume":"21","author":"Yang","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1093\/annonc\/mdx358_bb0215","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.12172","article-title":"Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression","volume":"160","author":"Zhang","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdx358_bb0220","doi-asserted-by":"crossref","first-page":"628.","DOI":"10.1182\/blood.V124.21.628.628","article-title":"A phase 2\/3 multicenter, randomized study comparing the efficacy and safety of lenalidomide versus investigator\u2019s choice in relapsed\/refractory DLBCL","volume":"124","author":"Czuczman","year":"2014","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx358_bb0225","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1034\/j.1600-0609.2001.00272.x","article-title":"Interferon alfa 2b as maintenance therapy in poor risk diffuse large B-cell lymphoma in complete remission after intensive CHOP-BLEO regimens","volume":"66","author":"Aviles","year":"2001","journal-title":"Eur J Haematol"},{"key":"10.1093\/annonc\/mdx358_bb0230","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx358_bb0235","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3324\/haematol.2015.125344","article-title":"Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial","volume":"100","author":"Jaeger","year":"2015","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdx358_bb0240","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/bjh.13652","article-title":"Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial","volume":"171","author":"Witzens-Harig","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdx358_bb0245","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3816\/CLML.2010.n.004","article-title":"Brief-duration rituximab\/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium","volume":"10","author":"Hainsworth","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1093\/annonc\/mdx358_bb0250","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/annonc\/mdp237","article-title":"Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma","volume":"20","author":"Haioun","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx358_bb0255","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00432-011-1074-1","article-title":"How to determine post-RCHOP therapy for risk-tailored adult patients with diffuse large B-cell lymphoma, addition of maintenance rituximab or observation: multicenter experience","volume":"138","author":"Huang","year":"2012","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1093\/annonc\/mdx358_bb0260","doi-asserted-by":"crossref","first-page":"e519","DOI":"10.3324\/haematol.2015.136622","article-title":"Efficacy of rituximab maintenance therapy for aggressive B-cell lymphoma depends on use of rituximab in induction therapy: a meta-analysis of randomized controlled trials","volume":"100","author":"Nannya","year":"2015","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdx358_bb0265","doi-asserted-by":"crossref","first-page":"378","DOI":"10.4103\/0366-6999.150111","article-title":"Rituximab treatment strategy for patients with diffuse large B-cell lymphoma after first-line therapy: a systematic review and meta-analysis","volume":"128","author":"Ren","year":"2015","journal-title":"Chin Med J (Engl)"},{"key":"10.1093\/annonc\/mdx358_bb0270","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1200\/JCO.2015.65.7171","article-title":"Randomized, double-blind, phase III trial of enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma","volume":"34","author":"Crump","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx358_bb0275","article-title":"PILLAR-2: a randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus in patients with poor-risk diffuse large B-cell lymphoma","volume":"34","author":"Witzig","year":"2016","journal-title":"J Clin Oncol (ASCO Annual Meeting Abstracts)"},{"key":"10.1093\/annonc\/mdx358_bb0280","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S2352-3026(16)30047-3","article-title":"mTOR inhibition in diffuse large B-cell lymphoma: new hope?","volume":"3","author":"Hess","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1093\/annonc\/mdx358_bb0285","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1016\/S2352-3026(16)30040-0","article-title":"Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial","volume":"3","author":"Johnston","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1093\/annonc\/mdx358_bb0290","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1016\/S2352-3026(17)30016-9","article-title":"Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial","volume":"4","author":"Ferreri","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1093\/annonc\/mdx358_bb0295","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2016.255","article-title":"Phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high\/high-intermediate risk diffuse large B-cell lymphoma","volume":"31","author":"Reddy","year":"2016","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdx358_bb0300","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.72.6984","article-title":"Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line R-CHOP","author":"Thieblemont","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx358_bb0305","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S1470-2045(14)70191-3","article-title":"Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial","volume":"15","author":"Vitolo","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx358_bb0310","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","article-title":"Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study","volume":"33","author":"Nowakowski","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx358_bb0315","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2217\/fon-2016-0130","article-title":"ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma","volume":"12","author":"Nowakowski","year":"2016","journal-title":"Future Oncol"},{"key":"10.1093\/annonc\/mdx358_bb0320","first-page":"289","article-title":"Improving survival and preventing recurrence of diffuse large B-cell lymphoma in younger patients: current strategies and future directions","volume":"6","author":"Karlin","year":"2013","journal-title":"Onco Targets Ther"},{"key":"10.1093\/annonc\/mdx358_bb0325","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","article-title":"Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma","volume":"29","author":"Ruan","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx358_bb0330","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1517\/14656566.2014.965142","article-title":"Bortezomib for the treatment of non-Hodgkin's lymphoma","volume":"15","author":"Bose","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"10.1093\/annonc\/mdx358_bb0335","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419345843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419345843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/28\/11\/2680\/21556047\/mdx358.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T18:58:03Z","timestamp":1750532283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419345843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":66,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0923753419345843"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdx358","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]}}}